A recent study from Umeå University in Sweden has unveiled significant findings on the connection between type 2 diabetes and Alzheimer’s disease. The research indicates that individuals with type 2 diabetes may face a heightened risk of developing Alzheimer’s due to impaired clearance of proteins linked to the disease.
Led by Professor Olov Rolandsson from the Department of Public Health and Clinical Medicine, the study highlights that type 2 diabetes may hinder the body’s ability to eliminate beta-amyloids—key proteins associated with Alzheimer’s-related plaques in the brain. This impairment could contribute to the increased cognitive risks observed in diabetic patients.
Impact of Beta-Amyloids on Cognitive Health
The researchers focused on two specific beta-amyloids, Aβ1-40 and Aβ1-42, and an enzyme responsible for breaking them down. They compared these factors in blood samples from a group of individuals with type 2 diabetes and a healthy control group. Both groups underwent a glucose infusion for four hours to induce acute hyperglycemia, followed by repeated blood sampling.
Initial results showed similar levels of beta-amyloids and the degrading enzyme in both groups immediately after the glucose infusion. However, while the control group exhibited a decrease in beta-amyloid levels and an increase in the enzyme responsible for their breakdown, the diabetic group showed no such changes. This suggests that individuals with type 2 diabetes may struggle to manage beta-amyloids effectively, potentially leading to their accumulation in the brain and an increased risk of cognitive disorders such as Alzheimer’s.
Significance and Future Directions
Professor Rolandsson emphasizes the importance of these findings for future research and potential treatment strategies. “These results could pave the way for new approaches to mitigate the risk of Alzheimer’s in people with type 2 diabetes,” he notes. “The study underscores the critical need for effective diabetes management and the prevention of high blood sugar episodes.”
The study involved ten participants with type 2 diabetes and eleven healthy controls, all aged between 66 and 72 years. While the findings are promising, Rolandsson calls for further research to validate these results and explore their implications for treatment.
This study, titled “Acute Hyperglycemia Induced by Hyperglycemic Clamp Affects Plasma Amyloid-β in Type 2 Diabetes,” was published on May 28, 2024, in the Journal of Alzheimer’s Disease.
Related topics:
ADA and Abbott Partner to Tackle Nutritional Needs in Diabetes and Obesity
Diabetes and Heart Disease: A Common Association
Eli Lilly’s Weight-Loss Drug Cuts Diabetes Risk, Long-Term Study Finds
